Company Overview - Green International Holdings Limited is an investment holding company primarily engaged in providing healthcare and medical services, beauty and fitness services, and comprehensive financial services including lending, securities brokerage, and asset management [2]. Financial Performance - As of December 31, 2024, Green International Holdings reported total revenue of 49.0894 million, representing a year-on-year growth of 8.56% [1]. - The company recorded a net profit attributable to shareholders of -0.7473 million, showing a significant year-on-year improvement of 92.41% [1]. - The gross profit margin stood at 59.8%, while the debt-to-asset ratio was 59.73% [1]. Stock Performance - As of May 27, the stock price of Green International Holdings closed at 0.6 HKD per share, marking an increase of 31.87% with a trading volume of 120,200 shares and a turnover of 68,100 HKD [1]. - Over the past month, the stock has experienced a cumulative decline of 20.18%, while year-to-date, it has increased by 12.35%, underperforming the Hang Seng Index by 16.06% [1]. Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -19.72 times, with a median of 0.3 times [1]. - Green International Holdings has a P/E ratio of -372.06 times, ranking 53rd in the industry [1]. - Comparatively, other companies in the sector have the following P/E ratios: Giant Medical Holdings at 0.23 times, Jingjiu Health at 0.38 times, Yongsheng Medical at 3.97 times, Global Medical at 4.58 times, and China Regenerative Medicine at 5.14 times [1].

（於開曼群島註冊成立之有限公司） （股份代號 : 2700） 2024 Green International Holdings Limited 格林國際控股有限公司 Annual Report 2024 年報 格林國際控股有限公司 二零二四年年度報告 目 錄 2 公司資料 3 主席報告書 4 管理層討論與分析 11 董事履歷 13 董事會報告 23 企業管治報告 40 環境、社會及管治報告 65 獨立核數師報告 70 綜合損益表 71 綜合損益及其他全面收益表 72 綜合財務狀況表 74 綜合權益變動表 75 綜合現金流量表 76 綜合財務報表附註 143 五年財務概要 格林國際控股有限公司 > 二零二四年年度報告 公司資料 董事會 執行董事 俞周杰先生 （主席） 余向進先生 Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1–1111 Cayman Islands 香港主要營業地點 非執行董事 陳漢鴻先生 劉東先生 周璀琼女士 （於2024年12月18日獲委任） 獨立非執行董事 吳洪先生 蔡大維先生 王春林先生 公司秘書 辛英楠先生 審 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任 何 損 失 承 擔 任 何 責 任。 GREEN INTERNATIONAL HOLDINGS LIMITED 格林國際控股有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：2700） 截 至2024年12月31日止年度 之年度業績公告 格 林 國 際 控 股 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）公 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至2024年12月31日止年度之綜合年度 業 績，連 同2023年 相 應 年 度 之 比 較 數 字 如 下： – 1 – 綜合損益表 截 至2024年12月31日止年度 | | | | | | | | | | | | 2024年 | 2023年 | | --- | --- | --- | --- | --- | --- | --- | --- | ...

3月31日，截至港股收盘，恒生指数下跌1.31%，报23119.58点。格林国际控股（02700.HK）收报0.5港 元/股，上涨11.11%，成交量7万股，成交额3.6万港元，振幅6.67%。 最近一个月来，格林国际控股累计涨幅12.5%，今年来累计涨幅11.11%，跑输恒生指数16.78%的涨幅。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 来源：金融界 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-18.88倍，行业中值2.45倍。格林国 际控股市盈率-39.17倍，行业排名第63位；其他巨星医疗控股（02393.HK）为0.25倍、京玖康疗 （00648.HK）为0.38倍、环球医疗（02666.HK）为4.52倍、永胜医疗（01612.HK）为4.58倍、中国再生 医学（08158.HK）为5.14倍。 资料显示，格林国际控股有限公司是一家投资控股公司,本集团主要从事提供(i)保健及医疗服务、(ii)美 容及健身服务、(iii)综合金融服务(包括放贷、证券经纪及资产管理)。 财务数据显示，截至 ...

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 25,921 thousand, a 3.2% increase from HKD 25,109 thousand in the same period of 2023[24] - Gross profit for the same period was HKD 14,034 thousand, up 14.9% from HKD 12,210 thousand year-on-year[24] - Loss before tax decreased to HKD 1,681 thousand, compared to a loss of HKD 4,789 thousand in the previous year, representing a 64.9% improvement[24] - Total comprehensive loss for the period was HKD 1,999 thousand, significantly reduced from HKD 5,077 thousand in the prior year, marking a 60.7% decrease[25] - The company reported a basic and diluted loss per share of HKD 0.23, an improvement from HKD 0.69 in the same period last year[24] - The group reported a net loss of HKD 1,609 million for the six months ended June 30, 2024, compared to a net loss of HKD 4,704 million for the same period in 2023, reflecting a reduction of 65.8%[46] - The group's net loss for the period was approximately HKD 1,609,000, a reduction of about 65.80% compared to HKD 4,704,000 in the previous year, primarily due to lower administrative expenses[77] Assets and Liabilities - Total assets as of June 30, 2024, were HKD 133,585 thousand, down from HKD 136,201 thousand at the end of 2023[26] - Current liabilities increased to HKD 66,153 thousand from HKD 64,551 thousand, reflecting a 2.5% rise[27] - Non-current assets decreased to HKD 54,416 thousand from HKD 56,183 thousand, a decline of 3.1%[26] - The company’s equity attributable to owners decreased from HKD (986,479) thousand at the beginning of the period to HKD (991,045) thousand by June 30, 2024[28] - As of June 30, 2024, the group had total assets of approximately HKD 133,585,000 and liabilities of about HKD 49,840,000, resulting in a debt-to-asset ratio of approximately 37.31%[82] - The current ratio as of June 30, 2024, was approximately 1.20, with current assets of about HKD 79,169,000 exceeding current liabilities of HKD 66,153,000[82] Cash Flow - For the six months ended June 30, 2024, the net cash generated from operating activities was HKD 3,089 thousand, compared to a net cash used of HKD 4,415 thousand in the same period of 2023[29] - The total cash and cash equivalents as of June 30, 2024, amounted to HKD 65,356 thousand, a decrease from HKD 72,265 thousand as of June 30, 2023[29] - Cash and cash equivalents decreased to HKD 65,356 thousand from HKD 66,826 thousand, a decline of 2.2%[26] - The cash flow from investing activities for the six months ended June 30, 2024, was HKD 1,223 thousand, compared to HKD 540 thousand in the same period of 2023[29] Segment Performance - The healthcare and medical segment generated revenue of HKD 1,882 million for the six months ended June 30, 2024, compared to HKD 1,187 million in the same period of 2023, representing a growth of 58.7%[46] - The beauty and fitness segment reported revenue of HKD 460 million for the six months ended June 30, 2024, down from HKD 1,704 million in the same period of 2023, indicating a decline of 73.0%[46] - The beauty and fitness business performance remained sluggish due to a sharp decline in the service industry and weak consumer market in China[69] Operational Changes and Strategies - The company aims to enhance market expansion and product development strategies in the upcoming quarters[19] - The group plans to close one beauty and fitness business location in the second half of 2024 to optimize cost efficiency and ensure strategic placement of its stores[70] - The company has faced challenges from market competitors in its healthcare and medical business segment[67] - The company has no immediate plans for significant acquisitions or expansions due to the cautious approach adopted in response to healthcare system reforms[79] Financial Risks and Compliance - The company continues to face various financial risks, including foreign exchange risk, credit risk, liquidity risk, and cash flow and fair value interest rate risk[37] - The company has adopted revised Hong Kong Financial Reporting Standards effective from January 1, 2024, which did not result in significant changes to the financial statements[34] - The board confirms compliance with the standards for securities trading as per the listing rules for the six months ending June 30, 2024[103] Shareholder Information - The board did not recommend any dividend payment for the six months ended June 30, 2024, consistent with the previous year[55] - The company expresses gratitude to shareholders, customers, suppliers, and banks for their continued support during the reporting period[106] Audit and Governance - The company has engaged an external consultant for internal audit functions, ensuring the adequacy and effectiveness of the risk management and internal control systems[102] - The audit committee consists of three independent non-executive directors, with one member holding recognized accounting qualifications and extensive experience in auditing and accounting[104] Employment and Legal Matters - The company employed 181 staff in Hong Kong and China as of June 30, 2024[93] - There were no significant ongoing or threatened litigations against the company or its subsidiaries[94]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任 何 損 失 承 擔 任 何 責 任。 GREEN INTERNATIONAL HOLDINGS LIMITED 格林國際控股有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：2700） 截 至2024年6月30日止六個月之 中期業績公告 格 林 國 際 控 股 有 限 公 司（「本公司」）之 董 事（「董 事」）會（「董事會」）宣 佈 本 公 司 及 其 附 屬 公 司（統 稱 為「本集團」）截 至2024年6月30日止六個月之未 經審核簡明綜合中期業績連同2023年 同 期 之 比 較 數 字。 本集團截至2024年6月30日止六個月之未經審核簡明綜合財務資料已由 本 公 司 審 核 委 員 會 審 閱。 – 1 – 簡明綜合損益表 截 至2024年6月30日止六個月 | --- | --- | --- | --- | |------ ...

2023 （於開曼群島註冊成立之有限公司） （股份代號 : 2700） Green International Holdings Limited 格林國際控股有限公司 Annual Report 2023 年報 格林國際控股有限公司 二零二三年年度報告 目 錄 執行董事 俞周杰先生 （主席） 余向進先生 非執行董事 陳漢鴻先生 劉東先生 獨立非執行董事 吳洪先生 蔡大維先生 王春林先生 145 五年財務概要 2 公司資料 3 主席報告書 4 管理層討論與分析 11 董事履歷 13 董事會報告 23 企業管治報告 40 環境、社會及管治報告 63 獨立核數師報告 68 綜合損益表 69 綜合損益及其他全面收益表 70 綜合財務狀況表 72 綜合權益變動表 73 綜合現金流量表 74 綜合財務報表附註 格林國際控股有限公司 > 二零二三年年度報告 公司資料 董事會 公司秘書 辛英楠先生 審核委員會 蔡大維先生 （委員會主席） 吳洪先生 王春林先生 註冊辦事處 香港股份過戶登記分處 卓佳證券登記有限公司 香港 夏愨道16號 遠東金融中心17樓 薪酬委員會 華僑永亨銀行有限公司 主要股份過戶登記處 Conyers T ...

Financial Performance - For the year ended December 31, 2023, the company reported total revenue of HKD 48,831,000, an increase of 3.4% from HKD 47,236,000 in 2022[4] - Gross profit for the same period was HKD 28,828,000, representing a 10.3% increase compared to HKD 26,147,000 in 2022[4] - The company recorded a net loss of HKD 8,791,000 for 2023, an improvement from a net loss of HKD 13,814,000 in 2022, indicating a reduction in losses by approximately 36.6%[5] - The total net loss before tax for the year was HKD 9,360,000, an improvement from a loss of HKD 13,857,000 in the previous year[34] - The group reported a pre-tax loss of HKD 1,465,000 in 2023, compared to a gain of HKD 1,176,000 in 2022[48] - The company reported a basic and diluted loss per share of HKD (1.61) for 2023, compared to HKD (2.00) in 2022, indicating an improvement in performance[52] Assets and Liabilities - The total assets decreased to HKD 136,201,000 in 2023 from HKD 168,637,000 in 2022, reflecting a decline of about 19.2%[7] - The company's total liabilities decreased to HKD 92,589,000 in 2023 from HKD 114,102,000 in 2022, a reduction of approximately 18.8%[8] - The company’s cash and cash equivalents decreased to HKD 66,826,000 in 2023 from HKD 81,742,000 in 2022, a decline of about 18.2%[7] - The total non-current assets in China were HKD 55,081,000 as of December 31, 2023, compared to HKD 68,704,000 in 2022[40][42] - The group's debt as of December 31, 2023, was approximately HKD 50.8 million, a decrease from HKD 72.5 million as of December 31, 2022, resulting in a leverage ratio of approximately 37.27%[86] Revenue Segmentation - The healthcare and medical segment generated approximately HKD 6,897,000 in revenue, while the beauty and fitness segment reported a loss of HKD 7,510,000 for the year ended December 31, 2023[34] - The healthcare and medical business generated revenue of HKD 31,212,000, while the beauty and fitness business contributed HKD 17,619,000 in 2023[43] - The group recognized other income of approximately HKD 5,066,000 in the healthcare and medical segment for the year ended December 31, 2023, compared to zero in 2022[35] Expenses and Cost Management - The company’s administrative expenses decreased to HKD 21,989,000 in 2023 from HKD 23,821,000 in 2022, a reduction of about 7.7%[4] - The group's direct costs and operating expenses for the year were approximately HKD 20,003,000, a decrease of about 5.15% compared to HKD 21,089,000 in 2022, primarily due to reduced merchandise costs[69] - Selling expenses for the year were approximately HKD 13,270,000, an increase of about 4.93% from HKD 12,647,000 in 2022, consistent with revenue growth[72] Accounting Policies and Standards - The group has applied new and revised Hong Kong Financial Reporting Standards for the first time starting from January 1, 2023, including HKFRS 17 on insurance contracts[16] - The application of HKAS 12 revisions has narrowed the exemption scope for deferred tax liabilities and assets, impacting the recognition of temporary differences[20] - The group anticipates that the application of the revised standards will not have a significant impact on its financial position or performance[21] - The revised HKAS 1 and HKFRS Practice Statement 2 clarify the definition of significant accounting policy information, which may influence financial reporting[17] - The group has adopted a new accounting policy for the disclosure of significant accounting policy information, which may affect how financial reports are interpreted[18] Operational Developments - The company continues to focus on expanding its healthcare and wellness services, aiming to enhance its market presence and product offerings in the coming years[11] - The healthcare and medical business faced increased operating expenses due to market competition and health measures implemented to mitigate pandemic threats[64] - Future expansion plans for the healthcare business have been slowed down due to the impact of healthcare reforms initiated in 2021[67] - The company has no intention to commit to any significant acquisitions or expansion plans until market responses to reforms stabilize[67] Governance and Compliance - The audit committee, consisting of three independent non-executive directors, has reviewed the consolidated financial statements for the year, confirming compliance with applicable accounting standards and listing rules[112] - The financial figures in the preliminary performance announcement have been verified by the group's auditor, ensuring consistency with the audited consolidated financial statements[113] - The annual performance announcement will be published on the Hong Kong Stock Exchange and the company's website, with the annual report to be sent to shareholders by April 30, 2024[114] Employee and Community Engagement - The group employed 179 employees in Hong Kong and China as of December 31, 2023[102] - The company expresses gratitude to its directors, employees, shareholders, customers, suppliers, banks, and business partners for their ongoing support[116]

（於開曼群島註冊成立之有限公司） （股份代號 : 2700） Green International Holdings Limited 格林國際控股有限公司 Interim Report 2023 中期報告 格林國際控股有限公司 • 2023年中期報告 目 錄 | 公司資料 | 2 | | --- | --- | | 簡明綜合損益表 | 4 | | 簡明綜合損益及其他全面收益表 | 5 | | 簡明綜合財務狀況表 | 6 | | 簡明綜合權益變動表 | 8 | | 簡明綜合現金流量表 | 9 | | 簡明綜合中期財務報表附註 | 10 | | 管理層討論及分析 | 28 | | 其他資料 | 37 | 格林國際控股有限公司 • 2023年中期報告 格林國際控股有限公司 • 2023年中期報告 公司資料 董事會 執行董事 俞周杰先生 （主席） 余向進先生 非執行董事 陳漢鴻先生 劉東先生 獨立非執行董事 吳洪先生 蔡大維先生 王春林先生 審核委員會 蔡大維先生 （委員會主席） 吳洪先生 王春林先生 薪酬委員會 蔡大維先生 （委員會主席） 俞周杰先生 吳洪先生 王春林先生 提名委員會 俞周杰先生 （委員會主席） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不 就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任 何損失承擔任何責任。 GREEN INTERNATIONAL HOLDINGS LIMITED 格 林 國 際 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號：2700） 截 至2023年6月30日 止 六 個 月 之 中 期 業 績 公 告 格 林 國 際 控 股 有 限 公 司（「本 公 司」）之 董 事（「董 事」）會（「董 事 會」）宣 佈 本 公 司 及 其 附 屬 公 司（統 稱 為「本 集 團」）截 至2023年6月30日 止 六 個 月 之 未 經審核簡明綜合中期業績連同2022年同期之比較數字。 本 集 團 截 至2023年6月30日 止 六 個 月 之 未 經 審 核 簡 明 綜 合 財 務 資 料 已 由 本公司審核委員會審閱。 ...